恒瑞医药(600276.SH)：第三季度净利润为13.01亿元，同比增长9.53%

Core Insights - Heng Rui Medicine (600276.SH) reported a revenue of 7.427 billion yuan for Q3 2025, representing a year-on-year growth of 12.72% [1] - The net profit attributable to shareholders for Q3 was 1.301 billion yuan, showing a year-on-year increase of 9.53% [1] - For the first three quarters, the company achieved a total revenue of 23.188 billion yuan, with a year-on-year growth of 14.85% [1] - The net profit attributable to shareholders for the first three quarters was 5.751 billion yuan, reflecting a year-on-year increase of 24.50% [1]